In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses

被引:44
作者
Co, Mary Dawn T. [1 ]
Orphin, Laura [1 ]
Cruz, John [1 ]
Pazoles, Pamela [1 ]
Green, Karin M. [2 ]
Potts, James [1 ]
Leporati, Anita M. [1 ]
Babon, Jenny Aurielle B. [1 ]
Evans, James E. [2 ]
Ennis, Francis A. [1 ]
Terajima, Masanori [1 ]
机构
[1] Univ Massachusetts, Sch Med, Ctr Infect Dis & Vaccine Res, Worcester, MA 01655 USA
[2] Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01655 USA
基金
美国国家卫生研究院;
关键词
T cells; Influenza; Vaccine; PERFORMANCE LIQUID-CHROMATOGRAPHY; LYMPHOCYTE MEMORY; INTERFERON-GAMMA; IMMUNE-RESPONSES; CLINICAL-TRIALS; HUMAN CD8(+); PROTECTION; TRIVALENT; NUCLEOPROTEIN; PROTEINS;
D O I
10.1016/j.vaccine.2008.09.092
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We evaluated three commercial trivalent inactivated vaccines (TIVs) from the 2007-2008 season in terms of their ability to elicit in vitro T cell responses. T cell-mediated immunity may offer a more cross-reactive vaccine approach for the prevention of pandemic or epidemic influenza. Human cytotoxic T cell lines demonstrated differences in matrix protein 1 and nucleocapsid protein recognition of autologous target cells. Peripheral blood mononuclear cells stimulated with each of the TIVs showed statistically significant differences between the vaccines in the numbers of IFN gamma producing cells activated. These data suggest that TIV vaccines are not similar in their ability to activate human T cell responses. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:319 / 327
页数:9
相关论文
共 41 条
[1]   AN INFLUENZA SPECIFIC T-KILLER CLONE IS RESTRICTED TO H-2LD AND CROSS-REACTS WITH DK REGION [J].
ASKONAS, BA ;
LIN, YL .
IMMUNOGENETICS, 1982, 16 (01) :83-87
[2]   Influenza vaccines: recent advances in production technologies [J].
Bardiya, N ;
Bae, JH .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2005, 67 (03) :299-305
[3]   Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children [J].
Belshe, RB ;
Gruber, WC .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES, 2001, 356 (1416) :1947-1951
[4]   Compromised influenza virus-specific CD8+-T-Cell memory in CD4+-T-cell-deficient mice [J].
Belz, GT ;
Wodarz, D ;
Diaz, G ;
Nowak, MA ;
Doherty, PC .
JOURNAL OF VIROLOGY, 2002, 76 (23) :12388-12393
[5]   DENGUE VIRUS-SPECIFIC CROSS-REACTIVE CD8+ HUMAN CYTO-TOXIC T-LYMPHOCYTES [J].
BUKOWSKI, JF ;
KURANE, I ;
LAI, CJ ;
BRAY, M ;
FALGOUT, B ;
ENNIS, FA .
JOURNAL OF VIROLOGY, 1989, 63 (12) :5086-5091
[6]   Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine [J].
Co, Mary Dawn T. ;
Orphin, Laura ;
Cruz, John ;
Pazoles, Pamela ;
Rothman, Alan L. ;
Ennis, Francis A. ;
Terajima, Masanori .
VACCINE, 2008, 26 (16) :1990-1998
[7]   CORRELATION OF LABORATORY STUDIES WITH CLINICAL RESPONSES TO A-NEW-JERSEY INFLUENZA VACCINES [J].
ENNIS, FA ;
MAYNER, RE ;
BARRY, DW ;
MANISCHEWITZ, JE ;
DUNLAP, RC ;
VERBONITZ, MW ;
BOZEMAN, FM ;
SCHILD, GC .
JOURNAL OF INFECTIOUS DISEASES, 1977, 136 :S397-S406
[8]   Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS) [J].
Ennis, FA ;
Cruz, J ;
Jameson, J ;
Klein, M ;
Burt, D ;
Thipphawong, J .
VIROLOGY, 1999, 259 (02) :256-261
[9]   Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection [J].
Garcia-Canas, Virginia ;
Lorbetskie, Barry ;
Bertrand, Diane ;
Cyr, Terry D. ;
Girard, Michel .
ANALYTICAL CHEMISTRY, 2007, 79 (08) :3164-3172
[10]   Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns [J].
Garcia-Canas, Virginia ;
Lorbetskie, Barry ;
Girard, Michel .
JOURNAL OF CHROMATOGRAPHY A, 2006, 1123 (02) :225-232